Literature DB >> 14574440

Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.

Magnus Ingelman-Sundberg1.   

Abstract

The cytochrome P450s are responsible for about 75% of phase I dependent drug metabolism and for the metabolism of a huge amount of dietary constituents and endogenous chemicals. The human has 59 active genes, and 6 of those encode important drug metabolising enzymes. About 40% of cytochrome P450 dependent drug metabolism is catalysed by polymorphic enzymes and such drug P450 interactions are frequently seen in adverse drug reaction reports. In this contribution an update of human cytochrome P450 enzymology and pharmacogenetics is given with particular emphasis on CYP1B1, CYP2B6, CYP2E1 and CYP3As.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14574440     DOI: 10.1007/s00210-003-0819-z

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  124 in total

1.  Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity.

Authors:  M A Robin; H K Anandatheerthavarada; J K Fang; M Cudic; L Otvos; N G Avadhani
Journal:  J Biol Chem       Date:  2001-04-26       Impact factor: 5.157

Review 2.  The role of CYP2B6 in human xenobiotic metabolism.

Authors:  S Ekins; S A Wrighton
Journal:  Drug Metab Rev       Date:  1999-08       Impact factor: 4.518

Review 3.  Study of P450 function using gene knockout and transgenic mice.

Authors:  Frank J Gonzalez; Shioko Kimura
Journal:  Arch Biochem Biophys       Date:  2003-01-01       Impact factor: 4.013

Review 4.  Inheritance and drug response.

Authors:  Richard Weinshilboum
Journal:  N Engl J Med       Date:  2003-02-06       Impact factor: 91.245

5.  Further characterization of the expression in liver and catalytic activity of CYP2B6.

Authors:  S Ekins; M Vandenbranden; B J Ring; J S Gillespie; T J Yang; H V Gelboin; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1998-09       Impact factor: 4.030

Review 6.  Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

Authors:  K Ito; T Iwatsubo; S Kanamitsu; K Ueda; H Suzuki; Y Sugiyama
Journal:  Pharmacol Rev       Date:  1998-09       Impact factor: 25.468

7.  Ligand-dependent maintenance of ethanol-inducible cytochrome P-450 in primary rat hepatocyte cell cultures.

Authors:  E Eliasson; I Johansson; M Ingelman-Sundberg
Journal:  Biochem Biophys Res Commun       Date:  1988-01-15       Impact factor: 3.575

8.  Characterization and functional analysis of two common human cytochrome P450 1B1 variants.

Authors:  R A McLellan; M Oscarson; M Hidestrand; B Leidvik; E Jonsson; C Otter; M Ingelman-Sundberg
Journal:  Arch Biochem Biophys       Date:  2000-06-01       Impact factor: 4.013

9.  Structural and functional characterization of the 5'-flanking region of the rat and human cytochrome P450 2E1 genes: identification of a polymorphic repeat in the human gene.

Authors:  Y Hu; J Hakkola; M Oscarson; M Ingelman-Sundberg
Journal:  Biochem Biophys Res Commun       Date:  1999-09-24       Impact factor: 3.575

10.  Detection and characterization of novel polymorphisms in the CYP2E1 gene.

Authors:  K S Fairbrother; J Grove; I de Waziers; D T Steimel; C P Day; C L Crespi; A K Daly
Journal:  Pharmacogenetics       Date:  1998-12
View more
  68 in total

1.  Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.

Authors:  Peter K Sand; Eric S Rovner; Jonathan H Watanabe; Michael G Oefelein
Journal:  Drugs Aging       Date:  2011-02-01       Impact factor: 3.923

Review 2.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

3.  Functional importance of a peripheral pocket in mammalian cytochrome P450 2B enzymes.

Authors:  Hyun-Hee Jang; Jingbao Liu; Ga-Young Lee; James R Halpert; P Ross Wilderman
Journal:  Arch Biochem Biophys       Date:  2015-08-28       Impact factor: 4.013

4.  Isolation and characterization of the CYP2D6 gene in Felidae with comparison to other mammals.

Authors:  Tamara Schenekar; Kathrin A Winkler; Jennifer L Troyer; Steven Weiss
Journal:  J Mol Evol       Date:  2010-12-28       Impact factor: 2.395

Review 5.  Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy.

Authors:  Magnus Ingelman-Sundberg; Cristina Rodriguez-Antona
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-08-29       Impact factor: 6.237

Review 6.  The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.

Authors:  Jose de Leon; Margaret T Susce; Elaina Murray-Carmichael
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

7.  Cell-based Models for Discovery of Pharmacogenomic Markers of Anticancer Agent Toxicity.

Authors:  Wei Zhang; R Stephanie Huang; M Eileen Dolan
Journal:  Trends Cancer Res       Date:  2008

8.  Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

Authors:  David Burger; Ilse van der Heiden; Charles la Porte; Marchina van der Ende; Paul Groeneveld; Clemens Richter; Peter Koopmans; Frank Kroon; Herman Sprenger; Jan Lindemans; Paul Schenk; Ron van Schaik
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

9.  Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes.

Authors:  János Magyar; Norbert Szentandrássy; Tamás Bányász; Valéria Kecskeméti; Péter P Nánási
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-26       Impact factor: 3.000

10.  Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform.

Authors:  Thomas J Long; Patrick A Cosgrove; Robert T Dunn; Donna B Stolz; Hisham Hamadeh; Cynthia Afshari; Helen McBride; Linda G Griffith
Journal:  Drug Metab Dispos       Date:  2016-09-12       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.